Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
340 GBX | -1.16% | +8.63% | +20.14% |
05-14 | Hutchmed announces trials of HMPL-306 and Surufatinib cancer therapies | AN |
05-14 | Hutchmed Starts Phase 2/3 Trial of Surufatinib Combination Therapy in Pancreatic Cancer | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+20.14% | 3.69B | |
+31.37% | 588B | |
-2.60% | 364B | |
+20.83% | 326B | |
+5.69% | 285B | |
+14.83% | 239B | |
+9.93% | 210B | |
-6.95% | 200B | |
+10.77% | 167B | |
+0.10% | 161B |
- Stock Market
- Equities
- HCM Stock
- News HUTCHMED (China) Limited
- Transcript : Hutchison China MediTech Limited, 2018 Earnings Call, Mar 11, 2019